In 2005, the Prostate Cancer Foundation and the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) initiated the Prostate Cancer Clinical Trials Consortium (PCCTC) in response to gaps identified in prostate cancer clinical research by physician investigators and prostate cancer advocates. The PCCTC is now a major multi-institutional clinical research organization consisting of a nationwide network of physicians at 13 academic institutions specializing in cutting-edge prostate cancer research with a single coordinating center located at Memorial Sloan-Kettering Cancer Center (MSKCC).

Capitalizing on their scientific expertise and unique institutional resources, Consortium members work together on one single mission – to design, implement and complete hypothesis-driven phase I/II and phase II trials in prostate cancer – translating scientific discoveries to improved standards of care for patients.

The Coordinating Center at MSKCC has created a new paradigm for collaborative drug development, implementing an organizational structure that allows for interactions between participating sites, trial sponsors, internal and external advisory boards, and regulatory agencies. This centralized management of all PCCTC research results in a uniformity of scientific priorities, standardized language for protocols and contracts, and centralized data management that ensure therapies are evaluated more efficiently.

A New Paradigm in Collaborative Drug Development